The University of Kansas Cancer Center is seeking a Hematologist/Oncologist with a focus in Blood and Marrow Transplantation and Cellular Immunotherapy to join the Division of Hematologic Malignancies and Cellular Therapeutics (HMCT) team. We are the region’s largest BMT and Cellular Immunotherapy program in Kansas.

Qualified candidates must have completed an ACGME accredited Hematology/Oncology fellowship, and be board certified/eligible in Hematology. Candidates who have completed a BMT fellowship program preferred.

Responsibilities:
• Provide medical care for both outpatient clinic and hospitalized patients
• Appointment on clinical scholar track
• Contribute to various research, educational and clinical initiatives related to areas of individual interest and expertise
• Advance the science of transplant and cellular therapeutics through participation in research, while staying abreast of changes to evidence-based medicine for patients with hematologic malignancies

Organization:
• The clinical service has experienced significant growth over the last decade, performing >300 transplants annually and has successfully performed >4,000 transplants since inception in 1977.
• The BMT and cellular therapeutics program operates a large, state-of-the-art, outpatient care facility, therapeutic blood treatment/apheresis center, and annually receives >1,000 referrals a year.
• The HMCT Division is comprised of leading experts in the treatment of hematologic malignancies and immune deficiencies, with 21 faculty members dedicated to seeking novel approaches to achieve more-effective outcomes while reducing or minimizing the short-and long-term effects of treatment, both in the laboratory and in state-of-the-art clinical facilities.
• NCI designated Cancer Center, with robust GMP and translational laboratory research facilities
• The University of Kansas Cancer Center has a distinguished teaching, research, and clinical faculty, which receives >$50 million in annual cancer research funding.
• FACT Accredited BMT and Immune Effector Cell (IEC) program that performs autologous and allogeneic transplants, CRISPR-Cas9 and CAR-T cell therapies for blood cancers and solid tumors.
• 910-bed academic medical center, and 49 bed unit for BMT, cellular therapeutics and hematologic malignancy patients. In 2021, the HMCT inpatient units will transition to a state-of-the-art 100-bed unit.
• The salary range is among the most competitive in the nation and is based on the qualifications

Kansas City:
• Bi-state population of greater than 2 million
• A “hidden gem” winning the award of America’s 4th most Cultured City by Travel+Leisure magazine
• Affordable housing including downtown lofts, suburban neighborhoods, and rural properties

For more information please contact:
Terri Houchen, Physician Recruiter
thouchen@kumc.edu 816-739-9975

Eamon Wood
Pharmaceutical Media, Inc.
Ewood@pminy.com (212) 904-0363